Similar articles

• Lyme borreliosis: perspective of a scientist-patient.

  Hamlen R. Hamlen R. Lancet Infect Dis. 2004 Oct;4(10):603-4. doi: 10.1016/S1473-3099(04)01138-7. Lancet Infect Dis. 2004. PMID: 15451481 No abstract available.
• Lyme carditis: a rare presentation in an unexpected setting.

  Robinson TT, Herman L, Birrer RB, Wallis KJ, Sama A. Robinson TT, et al. Am J Emerg Med. 1998 May;16(3):265-9. doi: 10.1016/s0735-6757(98)90098-5. Am J Emerg Med. 1998. PMID: 9596429 Review.
• Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.

  Pfister HW, Preac-Mursic V, Wilske B, Schielke E, Sörgel F, Einhäupl KM. Pfister HW, et al. J Infect Dis. 1991 Feb;163(2):311-8. doi: 10.1093/infdis/163.2.311. J Infect Dis. 1991. PMID: 1988514 Clinical Trial.
• Use of third-generation cephalosporins. Spirochetes.

  Luft B, Mariuz P. Luft B, et al. Hosp Pract (Off Ed). 1991;26 Suppl 4:34-9; discussion 53-4. doi: 10.1080/21548331.1991.11707733. Hosp Pract (Off Ed). 1991. PMID: 1918214 Review.
• Clinical and serologic follow-up in patients with neuroborreliosis.

  Treib J, Fernandez A, Haass A, Grauer MT, Holzer G, Woessner R. Treib J, et al. Neurology. 1998 Nov;51(5):1489-91. doi: 10.1212/wnl.51.5.1489. Neurology. 1998. PMID: 9818893